Pamelor and Multiple sclerosis - a phase IV clinical study of FDA data

Summary:

Multiple sclerosis is reported as a side effect among people who take Pamelor (nortriptyline hydrochloride), especially for people who are female, 50-59 old, also take Avonex, and have Insomnia.

The phase IV clinical study analyzes which people have Multiple sclerosis when taking Pamelor. It is created by eHealthMe based on reports of 3,798 people who have side effects when taking Pamelor from the FDA, and is updated regularly.

What is Pamelor?

Pamelor has active ingredients of nortriptyline hydrochloride. It is often used in migraine. eHealthMe is studying from 4,069 Pamelor users. Check the latest studies of Pamelor.

What is Multiple sclerosis?

Multiple sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath) is found to be associated with 1,088 drugs and 1,358 conditions by eHealthMe. Check the latest studies of Multiple sclerosis.

On Jul, 11, 2026

3,798 people reported to have side effects when taking Pamelor.
Among them, 27 people (0.71%) have Multiple sclerosis.

Among these 27 people:

What is the gender of people who have Multiple sclerosis when taking Pamelor? *

female: 70.37 %
male: 29.63 %

What is the age of people who have Multiple sclerosis when taking Pamelor? *

What are other drugs people take besides Pamelor? *

What are other side effects people have besides Multiple sclerosis? *

Pain In Extremity: 8 people, 29.63%
Multiple Sclerosis Relapse (reoccurrence of a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 6 people, 22.22%
Stress And Anxiety: 5 people, 18.52%
Convulsion (muscles contract and relax rapidly and repeatedly, resulting in an uncontrolled shaking of the body): 4 people, 14.81%
Feeling Abnormal: 4 people, 14.81%
Diabetes: 4 people, 14.81%
Fever: 4 people, 14.81%
Pneumonia: 4 people, 14.81%
Temperature Intolerance (inability to go in temperature): 4 people, 14.81%
Sepsis (a severe blood infection that can lead to organ failure and death): 4 people, 14.81%

What are the existing conditions these people have? *

Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 4 people, 14.81%
Insomnia (sleeplessness): 4 people, 14.81%
Pain: 3 people, 11.11%
Relapsing-Remitting Multiple Sclerosis (reoccurrence of an inflammatory disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged): 2 people, 7.41%
Nausea (feeling of having an urge to vomit): 2 people, 7.41%
Epigastric Discomfort: 2 people, 7.41%
Gastric Disorder (disease of stomach): 1 person, 3.70%
Acne (skin problems that cause pimples): 1 person, 3.70%
Arthritis (form of joint disorder that involves inflammation of one or more joints): 1 person, 3.70%
Blood Potassium Decreased: 1 person, 3.70%

* Approximation only. Some reports may have incomplete information.

Do you take Pamelor and have Multiple sclerosis?

- Check whether Multiple sclerosis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Pamelor:

Pamelor (4,069 reports)

Browse all side effects of Pamelor:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Multiple sclerosis:

Multiple sclerosis (1,088 drugs)

Browse all the conditions that are associated with Multiple sclerosis:

Multiple sclerosis (1,358 conditions)

Related publications that referenced our studies

Christopher KL, Elner VM, Demirci H, "Conjunctival Lymphoma in a Patient on Fingolimod for Relapsing-Remitting Multiple Sclerosis", Ophthalmic Plastic & Reconstructive Surgery, 2017 May .
Christopher, K. L., Elner, V. M., & Demirci, H. , "Conjunctival lymphoma in a patient on fingolimod for relapsing-remitting multiple sclerosis", Ophthalmic plastic and reconstructive surgery , 2014 Jan .
Christopher KL, Elner VM, Demirci H, "Conjunctival Lymphoma in a Patient on Fingolimod for Relapsing-Remitting Multiple Sclerosis", Ophthalmic Plastic & Reconstructive Surgery, 2017 May .
Christopher, K. L., Elner, V. M., & Demirci, H. , "Conjunctival lymphoma in a patient on fingolimod for relapsing-remitting multiple sclerosis", Ophthalmic plastic and reconstructive surgery , 2014 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on nortriptyline hydrochloride (the active ingredients of Pamelor) and Pamelor (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.